L'intérêt à découvert pour Bausch Health Companies donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Bausch Health Companies. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Bausch Health Companies (NYSE:BHC) Stock, Rapport sur les intérêts à découvert

Bausch Health Companies

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

Tech bull Dan Ives of Wedbush Securities has raised his price target for Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), signaling a 12% upside from its current trading price over the next 12 months.
What Happened: In a post on X, Ives expressed growing confidence in Palantir's artificial intelligence strategy and raised his target price on the stock to $160 per share, describing it as the company's "golden path to become an AI stalwart" over the next 12 months.
The bullish outlook comes as Palantir continues to leverage its AI Platform (AIP) to integrate data, decisions, and operations for clients, driving a 45% year-over-year increase in <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">U.S. commercial revenue</a> to $373 million in the first quarter of 2025. &#8211;
Ives' enthusiasm underscores his belief in the company's potential to dominate the AI landscape, despite its forward P/E ratio of 256.410, raising valuation concerns among some investors.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Raising price target on Palantir to $160 as our recent checks and growing confidence in the company&#39;s AI strategy is key to the bull thesis on Palantir playing out for the next 12 months. We believe Palantir has a &quot;golden path to become an AI stalwart the next few years &#x1f402;&#x1f525;&#x1f3af;&#x1f37f;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1943243085200138484?ref_src=twsrc%5Etfw">July 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Recently, Palantir partnered with BlueForge Alliance to <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies">digitize and accelerate U.S. warship production</a> for the Navy. The company is also negotiating to provide technology to the<a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies"> IRS and Social Security Administration</a>, strengthening its government footprint. 
Since Donald Trump's inauguration, Palantir has secured over <a href="https://www.benzinga.com/markets/tech/25/07/46278679/will-recent-events-dent-palantir-technologies-stock-385-growth">$113 million in contracts</a>, excluding a $795 million DoD deal.
However, controversy looms as states allege the Trump administration illegally shared Medicaid recipients' health data with immigration authorities, violating federal privacy laws.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46313514/warren-buffetts-quiet-dividend-play-9-high-yield-stocks-held-by-a-berkshire-subsidiary" target="_blank" rel="noreferrer noopener">Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary</a>
Why It Matters: Ives has been bullish on the stock, betting that it could triple in the coming years and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655507/tech-analyst-expects-palantir-stock-to-rise-above-400-as-ai-revolution-kicks-into-gear">trade above $400 per share</a>. 
"That's why it's the ‘Messi of AI.' I believe we're talking about a trillion-dollar market cap for Palantir in the next few years, and I think when you look at what [Alex] Karp and Palantir are doing, they, along with Nvidia, will be leading the AI revolution," Ives said in May.
Price Action: The stock was 0.25% in premarket on Thursday, but it has risen 90.36% on a year-to-date basis and 403.62% over the last year.
Twenty-five analysts, <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">tracked by Benzinga</a>, have set a consensus price target of $76.72 for Palantir with a consensus &#8216;sell&#8217; rating. The latest analyst ratings suggest a potential downside of 9.83% for the stock.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/PLTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="389" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063921/PLTR-ANR-new-fresh--1024x389.png" alt="" class="wp-image-979877" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063921/PLTR-ANR-new-fresh--1024x389.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063921/PLTR-ANR-new-fresh--300x114.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063921/PLTR-ANR-new-fresh--768x292.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063921/PLTR-ANR-new-fresh-.png 1296w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Benzinga Edge Stock Rankings shows that PLTR had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid at the 98.99th percentile, whereas its value ranking was poor at the 2.67th percentile; the details of all the metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="158" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063954/PLTR-edge-new-latest-1024x158.png" alt="" class="wp-image-979881" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063954/PLTR-edge-new-latest-1024x158.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063954/PLTR-edge-new-latest-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063954/PLTR-edge-new-latest-768x118.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10063954/PLTR-edge-new-latest.png 1284w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were slightly lower in premarket on Thursday. The SPY was down 0.095% at $623.47, while the QQQ declined 0.049% to $555.98, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-show-uncertainty-reigns-supreme">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image via Shutterstock

News

PLTR

Palantir Could Be The Next Big AI Winner, Says Dan Ives — Sees 12% PLTR Stock Surge

The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) announced today that comparable store net sales, for stores open at least one year, for the 5-week period ended July 5, 2025 increased 3.8 percent from comparable store net sales for the 5-week period ended July 6, 2024. Net sales for the 5-week fiscal month ended July 5, 2025 increased 4.7 percent to $106.5 million from net sales of $101.7 million for the prior year 5-week fiscal month ended July 6, 2024.
Comparable store net sales year-to-date for the 22-week period ended July 5, 2025 increased 3.9 percent from comparable store net sales for the 22-week period ended July 6, 2024. Net sales for the 22-week fiscal period ended July 5, 2025 increased 4.7 percent to $467.0 million compared to net sales of $446.2 million for the prior year 22-week fiscal period ended July 6, 2024.

Retail Sales

Buckle July Comp-Store Sales Up 3.8%, Net Sales Up 4.7% To $106.5M In July 2025 From $101.7M July 2024

Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) is looking for Q2 Adj EPS of $0.45-$0.60 vs $1.17 analyst estimate. sees sales of $408.000 million-$432.000 million vs $474.970 million analyst estimate.

Guidance

HELE

Helen Of Troy Sees Q2 Adj EPS $0.45-$0.60 vs $1.17 Est; Sees Sales $408.000M-$432.000M vs $474.970M Est

ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/ASML/earnings">opening bell on Wednesday, July 16.</a>
Analysts expect the Veldhoven, the Netherlands-based company to report quarterly earnings at $5.24 per share, up from $4.01 per share in the year-ago period. ASML projects to report quarterly revenue of $7.56 billion, compared to $6.24 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
ASML reported better-than-expected first-quarter earnings as its revenue and earnings per share beat analyst estimates on April 16.
ASML shares gained 0.7% to close at $799.83 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/asml/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Joseph Quatrochi maintained an Overweight rating and raised the price target from $840 to $890 on July 8, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Susquehanna analyst Mehdi Hosseini maintained a Positive rating and slashed the price target from $1,100 to $965 on April 17, 2025. This analyst has an accuracy rate of 68%.</li>
<li>JP Morgan analyst Sandeep Deshpande maintained an Overweight rating and cut the price target from $1,148 to $1,100 on Jan. 30, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying ASML stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ASML/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10020922/image-105-1024x579.png" alt="" class="wp-image-979408" style="width:695px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10020922/image-105-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10020922/image-105-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10020922/image-105-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10020922/image-105.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

ASML

Top Wall Street Forecasters Revamp ASML Expectations Ahead Of Q2 Earnings

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Antero Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>)</h3>
<ul class="wp-block-list">
<li>Antero Resources will issue its second quarter earnings release on Wednesday, July 30, after the close of trading on the New York Stock Exchange. The company's stock fell around 7% over the past five days and has a 52-week low of $24.53.</li>
<li>RSI Value: 28.4</li>
<li>AR Price Action: Shares of Antero Resources fell 2.9% to close at $35.56 on Wednesday.</li>
<li>Edge Stock Ratings: 43.15 Momentum score with Value at 59.89. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/ar"><img loading="lazy" decoding="async" width="428" height="175" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044517/image-110.png" alt="" class="wp-image-979661" style="width:333px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044517/image-110.png 428w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044517/image-110-300x123.png 300w" sizes="(max-width: 428px) 100vw, 428px" /></a></figure>
<h3 class="wp-block-heading">Expand Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On July 1, Mizuho analyst Nitin Kumar maintained Expand Energy with an Outperform rating and raised the price target from $141 to $142, while UBS analyst Josh Silverstein maintained the stock with a Buy and raised the price target from $144 to $145. The company's stock fell around 6% over the past five days and<a href="https://www.benzinga.com/quote/EXE"> has a 52-week low </a>of $69.12.</li>
<li>RSI Value: 27.8</li>
<li>EXE Price Action: Shares of Expand Energy fell 1.1% to close at $105.20 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0710">EXE stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0710"><img loading="lazy" decoding="async" width="930" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044710/image-111.png" alt="" class="wp-image-979665" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044710/image-111.png 930w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044710/image-111-300x268.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044710/image-111-768x686.png 768w" sizes="(max-width: 930px) 100vw, 930px" /></a></figure>
<h3 class="wp-block-heading">XCF Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>)</h3>
<ul class="wp-block-list">
<li>On July 8, XCF Global said it produced over 2.5 million gallons of SAF, renewable diesel, and naphtha at New Rise Reno Facility during ramp-up phase. &#8220;This update is simple but important: New Rise is producing renewable fuels&#8221; said Mihir Dange, Chief Executive Officer and Board Chair of XCF. &#8220;We&#8217;ve already produced over 2.5 million gallons of SAF, renewable diesel, and renewable naphtha, proving that our model works. Further, this is a testament to the dedication and expertise of our team, who are focused on executing our strategy and driving the clean fuel transition.&#8221; The company's stock fell around 94% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/SAFX"> low of $1.42.</a></li>
<li>RSI Value: 2.3</li>
<li>SAFX Ltd Price Action: Shares of XCF Global fell 6.8% to close at $1.50 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0710">SAFX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0710"><img loading="lazy" decoding="async" width="890" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044814/image-112.png" alt="" class="wp-image-979667" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044814/image-112.png 890w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044814/image-112-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10044814/image-112-768x706.png 768w" sizes="(max-width: 890px) 100vw, 890px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

SAFX

Top 3 Energy Stocks Which Could Rescue Your Portfolio For July

Helen Of Troy Says It Pursues Supplier Cost Cuts, Customer Price Hikes, And Regional Shift To Counter Tariff, Inflation Risks

Helen Of Troy Limited Targets China Tariff Exposure Below 25% By FY26 Through Global Production Diversification

<a href="https://www.globenewswire.com/Tracker?data=H7tQ72YHj5SGVujfdKJYQ-z3niO-XQqqFsUoixlLf_JOseKdHKL3pwrpWiTFhnMWCKAf1J1xHMH10-QV7QbBfsf40qImmsYrKwbVVtpfcZ6_sBJkvUpbq6Wc7ZTF0bh_a2tchltodSqtocQlod-7lorrbbk5_W86UTA6HBDAx5mUoCZGeuDQa-l2NIwStLN1f7_I-cDCZaBbxaAqEM3Nbiu9Emh57OvycxbFarYzGb4=">Pharvaris</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated the guidance for the disclosure of topline data from the ongoing RAPIDe-3 pivotal Phase 3 study evaluating deucrictibant immediate-release (IR) capsule for the on-demand treatment of HAE attacks. Pharvaris anticipates announcing topline data from RAPIDe-3 in the fourth quarter of 2025 and, pending positive data, expects to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026.

PHVS

Pharvaris Anticipates Reporting Topline Data From Rapide-3 In Q4 Of 2025; Expects To Submit NDA With FDA In H1 Of 2026

ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) has <a href="https://www.benzinga.com/topic/semiconductors">experienced an 8% decline</a> in market value year-to-date, contrasting sharply with the PHLX Semiconductor Index&#8217;s 14% gain during the same period. 
This underperformance for ON Semiconductor stems from a failure to achieve topline growth over the past two quarters, reflecting weakened demand across its core business segments, including power solutions, analog, and sensing technologies. 
The softness in these areas is largely attributable to challenging conditions within the automotive and industrial markets. Despite these headwinds, the stock has recently seen a significant surge, gaining over 47% in the last three months and outperforming the index&#8217;s 34% rise, and it currently trades above its 50-day moving average of $47.56.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45237744/on-semiconductor-sees-green-shoots-in-industrial-auto-shift-as-analysts-stay-cautious" rel="noreferrer noopener">ON Semiconductor Powers Through Expectations, But Analysts Dial Down Targets On Margin Squeeze</a>
<h2 class="wp-block-heading">Recent Financial Performance and Strategic Shifts</h2>
Several factors appear to be driving this recent upward trend. On May 5, ON Semiconductor announced its <a href="https://www.benzinga.com/news/earnings/25/05/45196247/on-semiconductor-q1-earnings-beat-estimates-ceo-optimistic-on-design-wins-despite-margin-decline">fiscal first-quarter 2025</a> revenue declined 22.4% year-on-year to $1.45 billion, yet this still surpassed the analyst consensus estimate of $1.40 billion. 
While revenue from power solutions, analog, and sensing all decreased, the company&#8217;s adjusted gross margin saw a 590 basis point decline to 40.0%, indicating pricing pressures within the semiconductor industry. Looking ahead, ON Semiconductor anticipates second-quarter adjusted revenue to be between $1.40 billion and $1.45 billion, aligning with the analyst consensus of $1.42 billion.
Further contributing to investor sentiment, on February 26, the company unveiled a <a href="https://www.benzinga.com/media/25/02/43971798/on-semiconductor-focuses-on-ai-chip-growth-to-cut-2400-jobs-to-stay-competitive">comprehensive restructuring plan</a> aimed at cost reduction and margin improvement across all business units, including manufacturing. This initiative involves laying off approximately 2,400 employees, with an expected annual savings of $105 million to $115 million by 2025. 
CEO Hassane El-Khoury emphasized a strategic shift towards core operations, phasing out side projects to capitalize on the increasing demand driven by artificial intelligence. El-Khoury specifically highlighted the critical role of the company&#8217;s power chips in supporting large-scale GPU deployments, underscoring strong AI tailwinds. 
This strategic focus on AI and cost optimization seems to resonate with investors. Previously, on February 10, the company had reported a 15% <a href="https://www.benzinga.com/25/02/43592322/on-semiconductor-q4-earnings-q4-revenue-drops-15-weak-demand-in-auto-and-industrial-sectors-lower-utilization-hits-margins-ceo-warns-of-continued-challenges-in-2025">revenue decline</a> for fiscal fourth-quarter 2024, missing analyst estimates, and El-Khoury had expressed uncertainty regarding 2025, making the recent strategic announcements all the more impactful.
<h2 class="wp-block-heading">Macroeconomic Tailwinds and Headwinds</h2>
Macroeconomic indicators also play a role in ON Semiconductor&#8217;s outlook. The proposed &#8220;Big Beautiful Bill&#8221; in the U.S. <a href="https://www.benzinga.com/markets/tech/25/07/46324642/arm-rides-ai-boom-and-outperforming-market">could significantly benefit</a> the company by increasing the U.S. chip investment tax credit to 30% through 2026, thereby encouraging domestic manufacturing expansion. 
While the bill also ends the $7,500 EV tax credit after September 30, potentially leading automakers to raise EV prices and boost margins, this could, in turn, create more room for investment in advanced chips, thus stimulating demand for ON Semiconductor&#8217;s products. 
However, the escalating U.S.-China geopolitical tensions, particularly the tariff war, pose a significant risk, with potential retaliatory measures from China. Automakers are actively seeking alternative <a href="https://www.benzinga.com/markets/tech/25/06/45833037/auto-industry-struggles-as-supply-chain-issues-threaten-production-amid-chinas-export-curbs-on-rare-earth-minerals-report">rare-earth material</a> sources to circumvent China&#8217;s export restrictions, developing low-to-zero rare-earth motors, and strengthening local supply chains, a sentiment echoed by Tesla&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Elon Musk.
<h2 class="wp-block-heading">Analyst Outlook</h2>
Analyst perspectives on ON Semiconductor are varied. A consensus price target from twenty-eight analysts stands at $62.43. Recent ratings from KeyBanc, Citigroup, and UBS suggest an average target of $60, implying a potential upside of 3.70% for the stock. 
In April, Bank of America analysts Vivek Arya and Duksan Jang anticipated a <a href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst">first-quarter earnings</a> beat due to conservative outlooks and tariff-related demand shifts favoring U.S. chipmakers. They projected a mixed second quarter, with expanded guidance ranges reflecting lingering uncertainties from trade tensions and AI regulation. 
These analysts also cautioned that ON Semiconductor could face a 7%-9% sales hit under modest to dire tariff scenarios, potentially leading to EPS declines ranging from 12% to 30% and margin pressure of 150-500 basis points. They specifically noted that companies tied to consumer and auto segments, like ON Semiconductor, are more vulnerable than AI- and cloud-exposed peers such as Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) or Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>). 
Earlier in January, Needham&#8217;s N. Quinn Bolton <a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns">highlighted weak demand</a> in the company&#8217;s key automotive and industrial markets and ongoing inventory digestion, expecting management to reduce fab utilization below 65%, which would pressure adjusted gross margins in the first half of 2025. Despite this near-term weakness, Bolton identified ON Semiconductor as a strong candidate for a semiconductor cycle rebound. 
Price Action: ON stock is trading higher by 0.09% to $57.82 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46328802/dell-hpe-named-top-ai-server-plays-as-analyst-cites-14b-backlog" target="_blank" rel="noreferrer noopener">Dell, HPE Named Top AI Server Plays As Analyst Cites $14B Backlog</a></li>
</ul>
Image via Shutterstock

Movers

Tech

LRCX

NVDA

TSLA

What's Fueling ON Semiconductor's Recent Stock Surge?

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The FDA has set a target action date of April 28, 2026, for the application under the Prescription Drug User Fee Act (PDUFA).
"Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "The health needs of people living with HIV often change over time – whether it's managing comorbidities or navigating complex medication regimens. We believe DOR/ISL, if approved, will represent an important new complete regimen option designed to help meet their diverse needs."
The NDA is based on findings at Week 48 of two pivotal Phase 3 clinical trials (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05631093%3Fterm%3Dislatravir%26page%3D2%26rank%3D20&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=MK-8591A-051&amp;index=1&amp;md5=19f532bbd62d49517c24c6053c9e0533">MK-8591A-051</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05630755&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=MK-8591A-052&amp;index=2&amp;md5=f8766e7f07603170fb6d72efa6249476">MK-8591A-052</a>) where DOR/ISL was demonstrated to be non-inferior to baseline antiretroviral therapy (bART) in the open-label trial MK-8591A-051 and non-inferior to bictegravir/emtrictabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in the double-blind trial MK-8591A-052. Across both trials, the safety profile of DOR/ISL was generally comparable to comparator baseline antiretroviral regimens in trial MK-8591A-051 and BIC/FTC/TAF in trial MK-8591A-052. Data from these trials <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmerck-announces-positive-data-from-phase-3-trials-that-show-the-investigational-once-daily-oral-two-drug-regimen-of-doravirine-islatravir-dor-isl-maintained-hiv-1-viral-suppression-at-week-48%2F%23%3A%7E%3Atext%3DMarch%252012%252C%25202025%252012%3A26%2520pm%2520ET.%2520DOR%2FISL%2Cto%2520comparator%2520antiretroviral%2520therapies%2520in%2520adults%2520with&amp;esheet=54288506&amp;newsitemid=20250710518672&amp;lan=en-US&amp;anchor=were+presented&amp;index=3&amp;md5=3764ef6f22589fe8271e55c80e83d584">were presented</a> during the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Government

Regulations

Merck's New Once-Daily HIV Pill Moves Closer to FDA Approval With April 2026 Decision Date

<ul>
<li>XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR)</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI&#xAE; (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis.
For patients treated with XTANDI plus leuprolide versus placebo plus leuprolide, EMBARK met the key secondary endpoint with a statistically significant and clinically meaningful improvement in OS. Results also showed a favorable trend towards improved OS for patients treated with XTANDI monotherapy versus placebo plus leuprolide, however the difference did not reach statistical significance. No new safety signals were observed in the analysis, and the safety results were consistent with the demonstrated safety profile of XTANDI.
XTANDI is currently approved in more than 80 countries, including in the United States, European Union, and Japan. Detailed OS results from EMBARK will be presented at a future medical meeting.
 &nbsp;

Pfizer And Astellas Pharma Report Topline Results From OS Analysis From Phase 3 EMBARK Study Evaluating XTANDI, In Combination With Leuprolide And As Monotherapy, In Men With nmHSPC With High Risk BCR

Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.90 by 54.65 percent. This is a 58.59 percent decrease over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $371.655 million which missed the analyst consensus estimate of $398.205 million by 6.67 percent. This is a 10.84 percent decrease over sales of $416.847 million the same period last year.

Earnings Misses

Helen Of Troy Q1 Adj. EPS $0.41 Misses $0.90 Estimate, Sales $371.655M Miss $398.205M Estimate

Billionaire investor Ray Dalio warned on Wednesday that President Donald Trump's latest round of tariffs could deepen "stagflation" and may never deliver on promises to revive U.S. factory floors.
What Happened: "The tariffs are being put into place as a symptom of things that are changing that will be there anyway," the Bridgewater Associates founder said in a video on X.
Dalio said the White House hopes levies will raise revenue and "develop manufacturing, which the United States needs both for employment reasons and security reasons." But he cast doubt on that outcome. "There is a belief that tariffs will bring manufacturing back to the United States, I am uncertain of that."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I've gotten a lot of questions on the recent Trump tariffs and their impact on the global economy. There is a belief that tariffs will bring manufacturing back to the United States, I am uncertain of that. You can learn more about why, and what the current big debt cycle the… <a href="https://t.co/GRlP1kiAOG">pic.twitter.com/GRlP1kiAOG</a>
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1942969885924925615?ref_src=twsrc%5Etfw">July 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The hedge-fund manager argued the world is shifting from decades of free-flowing capital and goods to "a more controlled world" where production is no longer done by the most efficient producer. "That creates less efficiency in the goods and services markets … and in the capital markets," he said, adding the result is "higher inflation and slower growth — more stagflation."
See also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46338091/dave-ramsey-tells-debt-laden-28-year-old-to-skip-courthouse-wedding-youll-tell-this-story-forever">Dave Ramsey Tells Debt-Laden 28-Year-Old To Skip Courthouse Wedding: &#8216;You&#8217;ll Tell This Story&#8217; Forever</a>
Why It Matters: Dalio's view echoes recent <a href="https://www.jpmorgan.com/insights/global-research/current-events/us-tariffs">forecasts</a> from J.P. Morgan and the OECD showing tariff-driven supply shocks shaving more than a point off <a href="https://www.oecd.org/en/about/news/press-releases/2025/06/global-economic-outlook-shifts-as-trade-policy-uncertainty-weakens-growth.html">global growth</a> next year. 
Trump's "reciprocal tariffs," which could reach 70% on some imports, are already rattling markets. Investors fear a replay of 2018's trade war, analysts <a href="https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a&amp;dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Fmarkets%2Ftrumps-tariff-gambit-puts-investors-on-edge-as-deadline-looms%2Fnews-story%2Ff6f04a89069fe2b1aabc5080bafabacc&amp;memtype=anonymous&amp;mode=premium&amp;v21=GROUPB-Segment-2-NOSCORE&amp;V21spcbehaviour=append">told</a> The Australian. Harvard economists estimate the April round alone could trim U.S. GDP by <a href="https://hbr.org/2025/04/understanding-the-global-macroeconomic-impacts-of-trumps-tariffs">1.4 percentage points</a> in 2025.
Dalio has been sounding alarms for months, telling his X followers that <a href="https://www.benzinga.com/personal-finance/25/05/45249352/ray-dalio-says-its-too-late-to-escape-tariff-damage-worries-u-s-will-be-bypassed">tariffs are "too late"</a> to fix de-globalization and risk leaving the U.S. "bypassed by the rest of the world." He&#8217;s also pointed out that the ballooning federal debt plus higher import costs will trigger "<a href="https://www.benzinga.com/markets/guidance/25/07/46266299/ray-dalio-forecasts-big-painful-disruptions-as-us-national-debt-set-to-swell-over-next-decade">big, painful disruptions</a>."
Trump argues import taxes will bankroll domestic tax cuts and force trading partners to negotiate. Yet critics say higher prices for inputs like steel already threaten U.S. exporters. Dalio called the policy shift "theoretical" and said whether it truly boosts American factories "is still a question mark."
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46337754/jim-cramer-says-a-tax-provision-in-trumps-one-big-beautiful-bill-could-gut-professional-gambling-heres-why-draftkings-fanduel-dont-mind">Jim Cramer Says A Tax Provision In Trump&#8217;s &#8216;One Big, Beautiful Bill&#8217; Could Gut Professional Gambling: Here&#8217;s Why DraftKings, FanDuel Don&#8217;t Mind</a></li>
</ul>
Image via Shutterstock

Economics

General

Ray Dalio Says Trump's Tariffs Are 'Theoretical,' Warns They May Not Bring Manufacturing Back To US

Wolfe Research analyst Steven Chubak upgrades Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) from Peer Perform to Outperform and announces $339 price target.

Upgrades

PIPR

Wolfe Research Upgrades Piper Sandler to Outperform, Announces $339 Price Target

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">FY 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings Per Share</td>
<td colspan="1" rowspan="1">$5.25 - $6.25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow ($B)</td>
<td colspan="1" rowspan="1">$3 - $4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Leverage2</td>
<td colspan="1" rowspan="1">Less than 2.5x</td>
</tr>
</tbody>
</table>
</figure>

Delta Air Lines Restores Its FY2025 Guidance: Sees Adj EPS $5.25-$6.25 vs $5.42 Est; Sees Free Cash Flow Of $3B-$4B

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is looking for Q3 Adj EPS of $1.25-$1.75 vs $1.34 analyst estimate..

Delta Air Lines Sees Q3 Adj EPS $1.25-$1.75 vs $1.34 Est; Revenue Expected To Increase 0%-4% YoY

HC Wainwright &amp; Co. analyst Sean Lee maintains Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) with a Buy and raises the price target from $2 to $13.

KZIA

HC Wainwright & Co. Maintains Buy on Kazia Therapeutics, Raises Price Target to $13

Trilogy Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#AMEX">TMQ</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.

Trilogy Metals Q2 EPS $(0.01), Inline

HC Wainwright &amp; Co. analyst Mike Colonnese downgrades Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Buy to Sell and lowers the price target from $305 to $300.

Downgrades

COIN

HC Wainwright & Co. Downgrades Coinbase Global to Sell, Lowers Price Target to $300

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) reported quarterly earnings of $2.10 per share which beat the analyst consensus estimate of $2.05 by 2.49 percent. This is a 11.02 percent decrease over earnings of $2.36 per share from the same period last year. The company reported quarterly sales of $16.65 billion which beat the analyst consensus estimate of $15.45 billion by 7.76 percent. This is a 0.06 percent decrease over sales of $16.66 billion the same period last year.

Earnings Beats

Delta Air Lines Q2 Adj. EPS $2.10 Beats $2.05 Estimate, Sales $16.65B Beat $15.45B Estimate

Legal

Press Releases

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Bausch Health Announces Filing of Supplement to Proxy Statement

Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Bausch Health Announces First Quarter 2025 Results

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

Bausch Health to Announce Second Quarter 2025 Results on July 30

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Comments

Bausch Health Companies

Intérêt court

Bausch Health Companies (NYSE:BHC) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL